St. Jude Medical gets FDA approval for QuickOpt timing cycle for heart disease

By Elaine Rigoli

Tampa, Fla., Aug. 22 - The Food and Drug Administration has approved the launch of St. Jude Medical, Inc.'s QuickOpt Timing Cycle Optimization, a new programmer feature designed to help physicians improve patient outcomes for people with cardiac resynchronization therapy defibrillator devices and traditional implantable cardioverter defibrillators.

The feature provides a programmer-based optimization method that provides comparable results to echocardiography.

St. Jude Medical said it developed QuickOpt optimization as an easy, practical and effective method for making the benefits of optimization more accessible to more patients.

QuickOpt provides the accuracy of echo-based optimization without the clinic time it takes to schedule, perform and interpret an echo procedure, officials noted.

The company said a recent study demonstrated that QuickOpt optimization correlates consistently with echo-based optimization more than 96%of the time for both atrial-ventricular timing and ventricular-ventricular timing.

Based in St. Paul, Minn., St. Jude Medical develops products for cardiac, neurological and chronic-pain patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.